In this issue of CHEST Clinical Perspectives, CHEST is undertaking primary research with pulmonologists and intensivists to understand their approach to ordering thromboprophylaxis in acutely ill medical patients for the purpose of reducing risk of VTE. Specifically, this issue focuses on the extent to which management practice has evolved given the introduction of novel anticoagulants. The objectives of this research are to:
- Understand current practice related to ordering thromboprophylaxis, as well as the therapies used with acutely ill medical patients.
- Understand the attitudes toward thromboprophylaxis from a risk and benefit standpoint that underlie decision-making related to deployment of therapy.
- Assess therapeutic, clinical, and administrative factors that impact management choices and the adoption of novel anticoagulants.
- Assess familiarity with and influence of the MAGELLAN study.
- Identify differences in management based on practice tenure and setting (academic vs community-based).